Deslorelin vs Melanotan II
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Deslorelin
Potent GnRH super agonist approximately 100× more potent than native GnRH. Used in veterinary medicine for estrus suppression and in human medicine for precocious puberty treatment. In research protocols, used for pituitary desensitization to reset the HPG axis or induce controlled medical suppression of sex hormone production.
Full profileMelanotan II
Melanotan II (MT-II) is a cyclic lactam analog of alpha-melanocyte stimulating hormone (α-MSH) that acts as a potent, non-selective melanocortin receptor agonist (MC1R, MC3R, MC4R, MC5R). Developed at the University of Arizona in the late 1980s, it produces eumelanin-driven skin darkening (tanning) via MC1R, sexual arousal and spontaneous erections via MC4R, and appetite suppression via MC3R/MC4R. Bremelanotide (PT-141) — now FDA-approved for female sexual dysfunction — was derived from Melanotan II.
Full profile| Deslorelin | Melanotan II | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | SuvaPryn, Ovuplant, D-His6-Pro9-Et-GnRH | MT-II, MTII, Cyclo[Nle4,D-Phe7]-α-MSH |
| Evidence | Research-stage | Research-stage |
| Dosing range | 50mcg–200mcg mcg, Daily SC for continuous suppression; single or short course for pituitary reset | 250mcg–1000mcg mcg, Daily during loading phase; 2–3x weekly for maintenance |
| Administration | Subcutaneous implant (veterinary), Subcutaneous injection | Subcutaneous injection (most common), Intranasal (less effective, lower bioavailability) |
| Key side effects | Hot flashes, Bone density loss (prolonged suppression), Suppression of testosterone or estrogen, Mood changes, irritability | Nausea (most common — especially first 30–60 minutes post-injection), Facial flushing, Spontaneous erections (males — often unwanted at higher doses), Fatigue / yawning post-injection |
| Cited sources | 2 references | 3 references |
Key differences
- Administration: Deslorelin — Subcutaneous implant (veterinary), Subcutaneous injection; Melanotan II — Subcutaneous injection (most common), Intranasal (less effective, lower bioavailability).
- Frequency: Deslorelin is typically Daily SC for continuous suppression; single or short course for pituitary reset; Melanotan II is Daily during loading phase; 2–3x weekly for maintenance.
- Research depth: this profile cites 2 sources for Deslorelin vs 3 for Melanotan II.
How each works
Deslorelin
Deslorelin produces a robust initial LH/FSH surge (flare effect) followed by profound, sustained pituitary desensitization with continued exposure. This biphasic response is consistent across all high-affinity GnRH super agonists. The flare phase is exploited for reproductive timing in veterinary medicine; the desensitization phase creates the clinical suppression used in precocious puberty and research HPG axis reset protocols.
Melanotan II
Melanotan II's broad melanocortin receptor agonism produces a constellation of effects across multiple systems. MC1R activation in melanocytes upregulates tyrosinase, the rate-limiting enzyme in melanin synthesis, producing UV-independent skin darkening. MC4R activation in the CNS and spinal cord drives sexual arousal and erectogenic effects more potent than most PDE5 inhibitors, and also produces appetite suppression and reduced food intake (the same pathway exploited by weight-loss drugs targeting the melanocortin system). MC3R activation contributes to energy homeostasis effects.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.